Increased plasma concentrations of risperidone and 9-hydroxyrisperidone occur in patients with severe renal impairment (creatinine clearance <30 mL/min/ m 2 ) treated with oral RISPERDAL ® ; an increase in the free fraction of risperidone is also seen in patients with severe hepatic impairment. Patients with renal or hepatic impairment should be carefully titrated on oral RISPERDAL ® before treatment with Risperdal Consta ® is initiated at a dose of 25 mg. A lower initial dose of mg may be appropriate when clinical factors warrant dose adjustment, such as in patients with renal or hepatic impairment [see Dosage and Administration () ] .
There is a wealth of evidence on the health hazards of glyphosate. Its approval, along with other hazardous chemicals, relies on systematic flaws in the EU and US regulatory processes, which to this day, do not require evaluation by independent research, and instead rely solely on the industry’s own studies. Approval is therefore often based on data not available to the public or independent research scientists. Nevertheless, raw data have been obtained from the industry through the law courts, which, when re-analysed by independent scientists, also provide evidence of toxicity.